Histone deacetylase inhibitors: A novel class of therapeutic agents in diabetic nephropathy

H. B. Lee, H. Noh, J. Y. Seo, M. R. Yu, H. Ha

Research output: Contribution to journalArticlepeer-review

47 Scopus citations

Abstract

Histone deacetylase (HDAC) inhibitors are currently being tested as anticancer agents in clinical trials. Chromatin remodeling, such as through histone acetylation, is a fundamental phenomenon in eukaryotic cell biology, bearing implications to numerous physiological and pathological phenomena. Here, we discuss recent data from our own laboratory and those of others demonstrating antifibrotic and renoprotective effect of HDAC inhibitors in diabetic kidneys, and the possible mechanisms including the role of reactive oxygen species. HDAC inhibitors may prove to be a novel class of multitarget agents in the treatment of diabetic nephropathy.

Original languageEnglish
Pages (from-to)S61-S66
JournalKidney International
Volume72
Issue numberSUPPL. 106
DOIs
StatePublished - Aug 2007

Keywords

  • Diabetic complications
  • Fibrosis
  • Histone acetylation
  • Histone deacetylase inhibitor
  • Hsp90
  • Reactive oxygen species

Fingerprint

Dive into the research topics of 'Histone deacetylase inhibitors: A novel class of therapeutic agents in diabetic nephropathy'. Together they form a unique fingerprint.

Cite this